The BEconneCTD-ILD Study

Thank you for your interest in this clinical research study for adults with interstitial lung disease (ILD) associated with connective tissue disease.

What is the BEconneCTD-ILD Study?

Clinical research studies help to improve the way doctors treat and prevent illnesses. The purpose of this study is to understand whether the study treatment can help improve lung function in people who have ILD (lung fibrosis) associated with connective tissue disease.

Already enrolled?

Simplified illustration of the lungs, BEconneCTD-ILD Study, interstitial lung disease, connective tissue disease

Who can participate?

To be considered for this study, you must meet these and other criteria:

Age

18 years of age or older

Medicine

Have ILD that is being treated with medicine now or has been treated with medicine in the past

Diagnosis

Have rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy (including polymyositis, dermatomyositis, and antisynthetase syndrome), Sjogren’s syndrome, or mixed connective tissue disease

What is the study treatment?

You will be assigned by chance to either the active study drug or a placebo. Neither you nor the study doctor and staff will know which one you are getting.

The placebo looks just like the study drug but contains no active medicine. This helps researchers understand the true effects of the study drug.

The study treatment is taken by injection once a week. You’ll be given instructions and shown how to self-inject.

Illustration of a female doctor and a potential male participant talk, BeconneCTD-ILD Study, interstitial lung disease

What happens
during the study?

The study consists of a Screening Period, a Study Treatment Period, an optional Long-Term Extension Study, and a final Safety Follow-up Visit.

Health checks and tests in this study

Screening Period

6 weeks
At least 1 clinic visit

The study team will collect information about your health and run tests to see if you qualify.

Study Treatment Period

52 weeks
7 scheduled clinic visits

You’ll be placed in a group by chance to receive either the active study drug or a placebo.

Long-Term Extension Study (Optional)

At least 52 weeks
(1 year)

After you complete the Study Treatment Period, you may be eligible to receive the active study drug (no placebo).

Safety Follow-up Visit

1 clinic visit

If you do not enter the Long-Term Extension Study, you will have a final Safety Follow-up Visit 8 weeks after your last dose of the study treatment.